Humacyte, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
HUMA$0.59+29.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets
(in thousands except for share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $64,523 | $50,497 |
| Inventory, net | 5,611 | 13,589 |
| Accounts receivable | 811 | 441 |
| Insurance recovery asset | 9,119 | — |
| Prepaid expenses and other current assets | 2,615 | 3,268 |
| Total current assets | 82,679 | 67,795 |
| Restricted cash | 209 | 209 |
| Property and equipment, net | 14,883 | 18,544 |
| Finance lease right-of-use assets, net | 27,801 | 29,146 |
| Other long-term assets | — | 672 |
| Total assets | $125,572 | $116,366 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,820 | $5,404 |
| Accrued expenses | 11,582 | 10,540 |
| Litigation settlement liability | 9,750 | — |
| Finance lease obligation, current portion | 609 | 2,428 |
| Total current liabilities | 24,761 | 18,372 |
| Long-term debt | 36,803 | 35,444 |
| Contingent Earnout Liability | 6,091 | 11,492 |
| Common stock warrant liabilities | 9,115 | 19,392 |
| Finance lease obligation, net of current portion | 29,070 | 26,974 |
| Other long-term liabilities | 1,668 | 1,583 |
| Total liabilities | 107,508 | 113,257 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 20,000,000 shares designated as of September 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 550,000,000 and 350,000,000 shares authorized as of September 30, 2026 and as of December 31, 2025, respectively; 277,798,105 and 193,000,611 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 28 | 20 |
| Additional paid-in capital | 814,843 | 729,937 |
| Accumulated deficit | (796,807) | (726,848) |
| Total stockholders’ equity | 18,064 | 3,109 |
| Total liabilities and stockholders’ equity | $125,572 | $116,366 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.